---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-23-000010"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T19:36:30.871333+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific amends $2.75B revolver: extends maturity to 2027, switches to SOFR, resets EBITDA exclusion base

## Summary
- Second amendment to $2.75B revolving credit agreement extends maturity from May 2026 to May 2027 for consenting lenders.
- LIBOR replaced with Term SOFR plus credit spread adjustments for Eurocurrency Rate for Dollars.
- Reference date for excluding Cash Litigation Payments from EBITDA reset from March 31, 2021 to December 31, 2022; cap remains $1B.
- Reference date for excluding restructuring charges from EBITDA also reset to December 31, 2022; cap remains $500M.
- Amendment effective March 1, 2023; Wells Fargo remains administrative agent.

## SEC filing metadata
- accession: 0000885725-23-000010
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572523000010/0000885725-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572523000010/bsx-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-23-000010
- JSON: https://secwatch.observer/filing/0000885725-23-000010.json
- Plain text: https://secwatch.observer/filing/0000885725-23-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.